From 26 to 28 November, ERAMET stepped into the heart of the UK pharmacokinetics community at Warwick Conferences, where the annual PKUK meeting gathered researchers, clinicians, and industry experts. From…
“Advancing the frontier of rare disease modeling: a critical appraisal of in silico technologies” is ERAMET's newest publication appearing in Nature Digital Medicine. This new article published on 17th November,…
ERAMET Project partner, Fondazione per la ricerca Farmacologica Gianni Benzi Onlus, will host the XVII edition of the Foresight Training Course, titled “From research to access: how does Europe speed…
ERAMET was proud to participate in PAGE 2025, held from June 3–6 at the Thessaloniki Concert Hall, where experts from across academia, regulatory agencies, and industry gathered to share and debate the latest in…
A new article has been published in Clinical and Translational Science, titled: AI-Driven Applications in Clinical Pharmacology and Translational Science: Insights From the ASCPT 2024 AI PreconferenceThe publication summarises key…
Brussels, 29 April 2025 – The ERAMET consortium is proud to announce the publication of a new article summarising the major achievements from its first year, marking a significant step…
On March 31st and April 1st, the ERAMET project held its second Face-to-Face Consortium Meeting, bringing together representatives from all partner institutions involved in the initiative. Hosted at the University…
The ERAMET project is transforming the development and approval of way drugs for rare and paediatric diseases. are developed and approved. With 30 million people affected by rare conditions across…
ERAMET Contributed to Draft ICH General Principles for MIDD GuidelineThe coordinators of the ERAMET project have actively participated in the development of the Draft ICH General Principles for Model-Informed Drug…
Last November, the ERAMET project was presented at this year’s Pharmacokinetics UK (PKUK) meeting, an important event where experts in drug research gather to share ideas and advancements. This two-day…